Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Akebia Therapeutics, Inc.AKBA · healthcare | |
|---|---|
| Grade |  C/Don the C/D boundary of 371 graded peers; percentile 61.6, sampling error 2.5 points; lower is stronger |
| Rank | 229 of 371 |
| Profitability | Cpercentile 43.8 |
| Solvency | Cpercentile 50.4 |
| Growth and financing | C/Dpercentile 61.8 |
| Reliability | 0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| Peer failure rate | 1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $120M to $591M assetstotal assets $376.6M[1] |
| Standard universe | insiderevenue above $1M and assets above $10M[1-2] |
| Warnings | none active · fortress balance sheetnot computable: distress |
| Inputs computable | 9 of 14 |
| Graded from | filings received through Feb 26, 2026225 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $0.822026-10-08; market equity $226.3M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Feb 26, 2026; the document on sec.gov.
We are a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. We have built a business focused on developing and commercializing innovative therapeutics that we believe serve as a foundation for future growth, including by contributing net product revenue to support the development and advancement of our robust pipeline of mid-stage programs targeting rare kidney diseases and early-stage programs targeting kidney disease and non-kidney focused indications. We have established the Company as a leader in the kidney community and believe our cross-organizational expertise in kidney disease positions us for success.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 43.8 | |||||||
| Gross profitability | 52.2% | [1-2,5] | 32.2% | 20.8 | 372 | 2025-12-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Accruals ratio | (24.6%) | [1,6-8] | (6.6%) | 17.5 | 811 | 2025-12-31 | |
| Gross margin stability, five years | 18.1 pts | [2,5,9-16] | 2.8 pts | 93.0 | 243 | 2025-12-31 | |
| Solvency, sleeve percentile 50.4 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (12.49) | [1,17-22] | (0.31) | 66.1 | 756 | 2025-12-31 | |
| Net debt to EBITDA | (5.51x) | [3-4,20,23] | 1.82x | 5.4 | 75 | 2025-12-31 | |
| Interest coverage | not computable | (4.51x) | |||||
| one or more required annual facts are missing | |||||||
| Current ratio | 1.55x | [17-18] | 2.96x | 79.6 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 61.8 | |||||||
| Revenue growth, three-year compound | (6.9%) | [2,9,11,13] | 10.0% | 82.9 | 415 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| pretax income must exceed the validity floor and imply a 0%-100% tax rate | |||||||
| Asset growth, three years | 1.9% | [1,8,24-25] | 2.1% | 47.2 | 704 | 2025-12-31 | |
| Net share issuance, one year | 13.4% | [26-27] | 2.5% | 55.5 | 634 | 2026-02-23 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.044; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 224 | Perspective Therapeutics, Inc. (CATX) Perspective Therapeutics, Inc. (CATX) C/Don the C/D boundary; percentile 60.3 NYSE · Pharmaceutical Preparations market equity $309.4M; last close $2.71 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | 60.3 | C/D | dilution, fortress balance sheet |
| 225 | ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals, Inc. (SPRY) C/Don the C/D boundary; percentile 60.5 Nasdaq · Pharmaceutical Preparations market equity $453.5M; last close $4.57 Warnings: short runway; 7 of 14 inputs | 60.5 | C/D | short runway |
| 226 | Twist Bioscience Corp. (TWST) Twist Bioscience Corp. (TWST) C/Don the C/D boundary; percentile 60.8 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $9.5B; last close $152.02 Warnings: fortress balance sheet; 9 of 14 inputs | 60.8 | C/D | fortress balance sheet |
| 227 | Teva Pharmaceutical Industries Ltd. (TEVA) Teva Pharmaceutical Industries Ltd. (TEVA) C/Don the C/D boundary; percentile 61.1 NYSE · Pharmaceutical Preparations market equity $45.7B; last close $39.22 No active warnings; 9 of 14 inputs | 61.1 | C/D | |
| 228 | Beam Therapeutics Inc. (BEAM) Beam Therapeutics Inc. (BEAM) C/Don the C/D boundary; percentile 61.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.5B; last close $24.59 No active warnings; 7 of 14 inputs | 61.4 | C/D | |
| 229 | Akebia Therapeutics, Inc. (AKBA) Akebia Therapeutics, Inc. (AKBA) C/Don the C/D boundary; percentile 61.6 Nasdaq · Pharmaceutical Preparations market equity $225.8M; last close $0.82 Warnings: fortress balance sheet; 9 of 14 inputs | 61.6 | C/D | fortress balance sheet |
| 230 | Mannkind Corp. (MNKD) Mannkind Corp. (MNKD) C/Don the C/D boundary; percentile 61.9 Nasdaq · Pharmaceutical Preparations market equity $1.1B; last close $3.42 No active warnings; 10 of 14 inputs | 61.9 | C/D | |
| 231 | Strata Critical Medical, Inc. (SRTA) Strata Critical Medical, Inc. (SRTA) C/Don the C/D boundary; percentile 62.2 Nasdaq · Services-Health Services market equity $395.4M; last close $4.46 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | 62.2 | C/D | short runway, fortress balance sheet |
| 232 | Embecta Corp. (EMBC) Embecta Corp. (EMBC) C/Don the C/D boundary; percentile 62.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $325.8M; last close $5.76 Warnings: late filer; 10 of 14 inputs | 62.4 | C/D | late filer |
| 233 | Biogen Inc. (BIIB) Biogen Inc. (BIIB) Dfourth fifth; percentile 62.7 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $32.2B; last close $218.35 No active warnings; 8 of 14 inputs | 62.7 | D | |
| 234 | Lenz Therapeutics, Inc. (LENZ) Lenz Therapeutics, Inc. (LENZ) Dfourth fifth; percentile 63.0 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $110.9M; last close $3.52 Warnings: short runway; 7 of 14 inputs | 63.0 | D | short runway |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | D | 62.8 | 2204 |
| sector peers, equal sleeves (the grade) | C/D | 61.6 | 371 |
| same exchange, equal sleeves | C/D | 61.3 | 1219 |
| sector peers, equal inputs | D | 63.8 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (66.3%) | 8.0% | 8 | hotter than 8 of 100 peers |
| Distance from 52-week high | (74.3%) | (31.4%) | 10 | closer to its high than 10 of 100 peers |
| EBIT to enterprise value | 19.6% | (1.5%) | 98 | pricier than 2 of 100 peers |
| Free cash flow yield | 30.0% | (1.0%) | 97 | pricier than 3 of 100 peers |
| Book value to price | 0.11 | 0.28 | 28 | pricier than 72 of 100 peers |
| Sales to price | 1.05 | 0.31 | 84 | pricier than 16 of 100 peers |
| Composite equity issuance, five years | 59.1% | 20.3% | 68 | more equity-funded than 68 of 100 peers |
| Relative strength against the sector, log excess return | (1.30) | (0.14) | 8 | ahead of 8 of 100 peers |
Inputs: market equity $225.8M; EBIT $23.5M; free cash flow $67.7M; book equity $25.0M; sales $236.2M; debt $49.6M; cash $155.5M[28].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: 7 of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (2.4%) | ✗ fail[6,8] |
| Operating cash flow above zero | $68.0M | ✓ pass[7] |
| Return on assets improved | 26.3 pts | ✓ pass[6,8,24,29] |
| Operating cash flow exceeds net income | $73.3M | ✓ pass[6-7] |
| Long-term leverage fell | (0.6 pts) | ✓ pass[1,8,24,30-31] |
| Current ratio improved | 14.6 pts | ✓ pass[17-18,32-33] |
| No new shares issued | 13.4% | ✗ fail[26-27] |
| Gross margin improved | 22.7 pts | ✓ pass[2,5,9-10] |
| Asset turnover improved | 40.8 pts | ✓ pass[2,8-9,24] |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $155.5M[34] |
| Operating cash flow, four quarters | $41.6M[7,34-38] |
| Months of runway | not finite |
| trailing operating cash flow is nonnegative, so runway is not finite | |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 65 |
| 10-Q received Aug 5, 2026 | |
| Median daily dollar volume | $5.0M |
| 63 sessions | |
| Days since newest grade input | 225 |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $376.6M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $236.2M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $184.8M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 4 | total debt | us-gaap:LongTermDebt | $48.2M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 5 | cost of revenue | us-gaap:CostOfRevenue | $39.5M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 6 | net income | us-gaap:NetIncomeLoss | -$5.3M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 7 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $68.0M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 8 | assets | us-gaap:Assets | $220.7M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $160.2M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 10 | cost of revenue | us-gaap:CostOfRevenue | $63.2M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $194.6M | 2023-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 12 | cost of revenue | us-gaap:CostOfRevenue | $74.1M | 2023-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $292.5M | 2022-12-31 | 2024-03-14 | 10-K | filing · viewer · series |
| 14 | cost of revenue | us-gaap:CostOfRevenue | $85.6M | 2022-12-31 | 2024-03-14 | 10-K | filing · viewer · series |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | $211.7M | 2021-12-31 | 2023-08-28 | 10-K/A | filing · viewer · series |
| 16 | cost of revenue | us-gaap:CostOfRevenue | $150.7M | 2021-12-31 | 2023-08-28 | 10-K/A | filing · viewer · series |
| 17 | current assets | us-gaap:AssetsCurrent | $253.0M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 18 | current liabilities | us-gaap:LiabilitiesCurrent | $162.9M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 19 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$1.7B | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 20 | operating income | us-gaap:OperatingIncomeLoss | $23.5M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 21 | book equity | us-gaap:StockholdersEquity | $32.6M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 22 | liabilities | us-gaap:Liabilities | $344.0M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 23 | depreciation amortization | us-gaap:Depreciation | $1.3M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 24 | assets | us-gaap:Assets | $241.7M | 2023-12-31 | 2025-03-13 | 10-K | filing · viewer · series |
| 25 | assets | us-gaap:Assets | $356.1M | 2022-12-31 | 2024-03-14 | 10-K | filing · viewer · series |
| 26 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 267,879,239 | 2026-02-23 | 2026-02-26 | 10-K | filing · viewer · series |
| 27 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 236,231,057 | 2025-03-10 | 2025-03-13 | 10-K | filing · viewer · series |
| 28 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 277,106,245 | 2026-07-31 | 2026-08-05 | 10-Q | filing · viewer · series |
| 29 | net income | us-gaap:NetIncomeLoss | -$69.4M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 30 | long term debt | us-gaap:LongTermDebtNoncurrent | $48.2M | 2025-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 31 | long term debt | us-gaap:LongTermDebtNoncurrent | $38.7M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 32 | current assets | us-gaap:AssetsCurrent | $113.8M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 33 | current liabilities | us-gaap:LiabilitiesCurrent | $80.9M | 2024-12-31 | 2026-02-26 | 10-K | filing · viewer · series |
| 34 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $155.5M | 2026-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
| 35 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$17.7M | 2026-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$21.2M | 2026-03-31 | 2026-05-07 | 10-Q | filing · viewer · series |
| 37 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $36.9M | 2025-09-30 | 2025-11-10 | 10-Q | filing · viewer · series |
| 38 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $8.8M | 2025-06-30 | 2026-08-05 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 61.6 is 1.6 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
